Evaluating the Safety and Immunogenicity of Polyvalent DNA and Recombinant gp120 Protein HIV Vaccine (PDPHV) in Healthy, HIV-uninfected Adults

The purpose of the study is to evaluate the safety, tolerability, and immunogenicity of polyvalent env (A,B,C,A/E)/gag (C) DNA prime and gp120 (A,B,C,A/E) protein HIV-1 vaccines boost (PDPHV) with either Alhydrogel or GLA-SE in healthy, HIV-uninfected adults. Volunteers will receive either the PDPHV or the placebo (normal saline) by intramuscular injections. Some volunteers will receive Alhydrogel and others will receive GLA-SE as part of the protein boost.

NCT Number	NCT07675629
Lead Sponsor	Worcester HIV Vaccine Collaborators: Desmond Tutu Health Foundation, Brigham and Women's Hospital
Conditions	HIV Prevention
Enrollment	126 participants
Start Date	2026-09-01
Primary Completion	2028-08-31 (estimated)
Study Completion	2029-08 (estimated)
Updated on ClinicalTrials.gov	2026-06-30